SecBot SecBot
Biotech Drug Report Generated Jul 10, 2026

CUE-401

CUE·Cue Biopharma, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Preclinical
Time to market
Unknown, earliest Phase 1 initiation expected year-end 2026; even if successful, Phase 2/3 and approval would take many years
Why 4/10
CUE-401 is still preclinical (IND not yet filed). The next catalyst is IND submission targeted for H2 2026, with Phase 1 initiation expected by year-end 2026, a soft timeline, not a hard dated binary. As a preclinical asset, no PDUFA or pivotal readout exists to drive a large binary move in the next ~12 months.
Actionable Insight NEUTRAL

CUE-401 is the company's lead autoimmune candidate but remains preclinical. The stock has significant non-CUE-401 catalysts: a Phase 2 data readout for CUE-221 (anti-IgE) expected H2 2026, plus recent $50M and $30M financings that extend runway. Watch for the IND filing timeline, any delay beyond H2 2026 would be a negative signal.

Price Chart

Loading chart...

Executive Summary

CUE-401 is Cue Biopharma's lead preclinical autoimmune asset, a first-in-class bispecific fusion protein combining modified TGF-β and IL-2 to expand regulatory T cells (Tregs). It has received positive FDA Pre-IND feedback and preclinical data shows good tolerability. IND submission is targeted for H2 2026 with Phase 1 by year-end. While the science is differentiated, CUE-401 is years from commercialization, the company has a going-concern history (partially addressed by recent $50M and $30M financings), and the stock has multiple catalysts beyond CUE-401 including a Phase 2 readout for CUE-221 (anti-IgE) in H2 2026.

How It Works

CUE-401 is a single injected protein that combines two signaling molecules, TGF-β and IL-2, both modified for safety. Together, they work to turn down the immune system by expanding "regulatory T cells" (Tregs), which act like the body's natural peacekeepers. The goal is to re-establish immune tolerance in autoimmune diseases (where the immune system mistakenly attacks the body) without broadly suppressing the entire immune system.

Trial Status

CUE-401 is in preclinical development. Cue Biopharma received positive Pre-IND feedback from the FDA in June 2025 and presented preclinical safety/tolerability data in February 2026 showing no adverse events in two non-GLP animal studies. IND submission is targeted for H2 2026, with a first-in-human Phase 1 study expected to begin by year-end 2026.

The Two-Sided Case

▲ Bull Case5
First-in-class bispecific mechanism combining TGF-β and IL-2 to induce and expand Tregs, a novel approach to restore immune tolerance in autoimmune disease, supported by Nobel Prize-winning Treg research
Positive FDA Pre-IND feedback received in June 2025 de-risks regulatory pathway; preclinical safety data (Feb 2026) showed CUE-401 was well tolerated with no adverse events in animal studies
Collaboration with Ono Pharmaceutical (2023) provides non-dilutive R&D funding and a potential co-development/commercialization partner for the U.S. market
Recent $50M private placement (July 2026 led by Cormorant Asset Management) plus $30M financing (May 2026) and $7.5M Boehringer Ingelheim milestone payment significantly strengthen the balance sheet and extend cash runway past near-term going-concern fears
Autoimmune disease market is massive (hundreds of billions globally); a novel Treg-inducing agent with disease-modifying potential could capture significant share
▼ Bear Case5
CUE-401 is still preclinical, IND not yet filed, no human safety or efficacy data exists. IND timeline slipped from Q2 2026 to H2 2026, signaling potential development delays
Company had substantial doubt about going concern as recently as March 2026 (10-K filing). While recent financings help, the 1-for-30 reverse split (April 2026) to maintain Nasdaq listing signals distress
Highly competitive Treg-modulating space: Amgen, Nektar (Rezpeg), TRexBio, and others are pursuing similar or adjacent approaches, some already in the clinic
The company has high cash burn (~$38M annual R&D spend reported) and even with recent $50M+$30M raises, profitability is years away with no approved products generating revenue
CUE-401's novel dual-cytokine mechanism carries inherent safety risk, both TGF-β and IL-2 are powerful cytokines with potential for off-target effects despite the engineered modifications

Upcoming Catalysts

  • IND submission for CUE-401 (expected H2 2026)
  • Phase 1 first-in-human study initiation (expected by year-end 2026)
  • CUE-221 Phase 2 data readout in chronic spontaneous urticaria (H2 2026), a separate pipeline catalyst
  • Potential partnership or option exercise by Ono Pharmaceutical for CUE-401

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Cue Biopharma, Inc. Press Release CUE ·Originating report

Sources · 14

Hover a chip for the title
1 nasdaq.com2 biospace.com3 americanbankingnews.com4 stocktitan.net5 sahmcapital.com6 ono-pharma.com7 marketchameleon.com8 cuebiopharma.com9 cuebiopharma.com10 sec.gov11 sec.gov12 marketbeat.com13 synapse.patsnap.com14 owler.com